Showing results (1551-1560 of 3,792) with videos related to
Sort By:
Pageof 380
Oncoimmunology|October 10, 2015
Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future developmentYunching Chen, Dan G DudaOncoimmunology|October 10, 2015
A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3William W Greenfield, Shawna L Stratton, Rebecca S Myrick, et al.Oncoimmunology|October 10, 2015
Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinomaHuamin Wang, Xiaoping Su, Mingjin Yang, et al.Oncoimmunology|October 10, 2015
Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanomaPanagiotis Karagiannis, Federica Villanova, Debra H Josephs, et al.Oncoimmunology|October 10, 2015
An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effectsHyun-Il Cho, Soo-Hyun Jung, Hyun-Jung Sohn, et al.Oncoimmunology|August 8, 2014
Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8+ tumor-infiltrating lymphocytes in ovarian cancerJohn R Webb, Katy Milne, Brad H NelsonOncoimmunology|August 13, 2014
Tumor-associated autoantibodies correlate with poor outcome in prostate cancer patients treated with androgen deprivation and external beam radiation therapyLisa Ds Johnson, Nancy J Nesslinger, Paul A Blood, et al.Oncoimmunology|August 13, 2014
STING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expressionNina Le Bert, Adeline R Lam, Samantha Sw Ho, et al.Oncoimmunology|August 13, 2014
The fatal alliance of cancer and T cells: How pancreatic tumor cells gather immunosuppressive T cellsEvelin Grage-Griebenow, Heiner Schäfer, Susanne SebensOncoimmunology|July 23, 2014
Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak® on CD25+ cellsManfred B Lutz, Andreas S Baur, Beatrice Schuler-Thurner, et al.Pageof 380